Cambridge Investment Research Advisors Inc. Purchases 2,177 Shares of Amgen Inc. $AMGN

Posted by Geri Gentry on May 18th, 2026

Cambridge Investment Research Advisors Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.1% during the fourth quarter, Holdings Channel reports. The fund owned 107,606 shares of the medical research company’s stock after acquiring an additional 2,177 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Amgen were worth $35,220,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in AMGN. Anfield Capital Management LLC increased its stake in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Dogwood Wealth Management LLC increased its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the last quarter. Board of the Pension Protection Fund bought a new position in Amgen in the fourth quarter valued at $26,000. Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new stake in Amgen during the fourth quarter valued at about $33,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $326.31 on Monday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a one year low of $267.73 and a one year high of $391.29. The company has a 50-day simple moving average of $349.17 and a two-hundred day simple moving average of $343.36. The firm has a market capitalization of $176.10 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 3.28 and a beta of 0.44.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the business posted $4.90 earnings per share. Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts anticipate that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen’s dividend payout ratio (DPR) is 70.15%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.85% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have issued reports on AMGN. Leerink Partners restated a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price target on shares of Amgen in a research report on Wednesday, April 8th. Canaccord Genuity Group began coverage on shares of Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Finally, Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $356.15.

Read Our Latest Report on Amgen

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.